Fearless Rose Ribbon Testicular Cancer Awareness Shirt, Hoodie, Tank top, Sweater

Research shows that advanced molecular imaging such as with PET Axumin is a useful addition to standard imaging to guide decisions about which patients may benefit from radiotherapy after resection. Prostate, Dr. Ashesh Jani, professor of radiation oncology at Emory University Winship Cancer Institute and colleagues concluded.

Fearless Rose Ribbon Testicular Cancer Awareness Shirt, Hoodie, Tank top, Sweater

Managing cancer patients after prostatectomy can be challenging as prostate-specific antigen (PSA) levels continue to increase in a large subset (20% to 40%). , signaling recurrence. But the Fearless Rose Ribbon Testicular Cancer Awareness Shirt, Hoodie, Tank top, Sweater failure rate is high with post-surgery radiation therapy, Jani noted.
The researchers note that molecular imaging helps to identify patients with the ectopic disease and are unlikely to benefit from radiotherapy and accurately locate prostate cancer recurrence. Furthermore, the researchers reported that the safety results were acceptable, with no significant difference in serious gastrointestinal or genital side effects between the Fearless Rose Ribbon Testicular Cancer Awareness Shirt, Hoodie, Tank top, Sweater two study groups.

“Although previous PET studies have led to changes in the way prostate cancer is administered, further improvement in patient outcomes has not been proven until this point.” a statement from ASTRO about the data.

During a press conference at the ASTRO meeting, the moderator, Dr. Sue Yom, described the 12% difference to the main end of the regular image versus the regular image plus PET as “very impressive. It is very rare to see that kind of change to imaging interventions on hard cancer endpoints in one trial, “added.

The authors recommend that PET be included in the Fearless Rose Ribbon Testicular Cancer Awareness Shirt, Hoodie, Tank top, Sweater evaluation of patients with increased PSA levels for best results, but they also acknowledge that although fluciclovine was approved by the US Food and Drug Administration in 2016 and Already included in the National Cancer Guidelines for Cancer Treatment, it is not yet widely used for radiation treatment planning. Research shows that some insurance companies do not want PET coverage, including its use for recurrent prostate cancer assessment, citing a lack of supportive data.